2024 World Conference on Lung Cancer (WCLC) - Posters-P3.12E.05 Real-World Comparative Effectiveness of Sotorasib vs Docetaxel as 2L/2L+ Treatment of KRAS G12c-Mutated Advanced NSCLC

P3.12E.05 Real-World Comparative Effectiveness of Sotorasib vs Docetaxel as 2L/2L+ Treatment of KRAS G12c-Mutated Advanced NSCLC

Back to course

Pdf Summary

The study, "Real-world Comparative Effectiveness of Sotorasib vs Docetaxel as Second-line (2L) or Higher Treatment of KRAS G12C-mutated Advanced NSCLC," investigates the effectiveness of sotorasib—a selective KRASG12C inhibitor—compared to docetaxel in patients with advanced non-small cell lung cancer (NSCLC) that exhibits the KRAS G12C mutation. The analysis draws on real-world data to offer insights beyond clinical trial findings and evaluates treatment in a post-immunotherapy landscape.<br /><br />**Key Findings:**<br /><br />1. **Overall Survival (OS):** Sotorasib demonstrated a longer median OS compared to docetaxel in both second-line and higher (2L) treatment settings. The hazard ratio (HR) was 0.62 for 2L and 0.65 for 2L settings after adjusting through propensity score-weighted methods, indicating a 38-35% reduced risk of death with sotorasib.<br /><br />2. **Subgroup Consistency:** The improved survival benefit of sotorasib held true across various subgroups, including patients with histories of smoking, those with non-squamous cell carcinoma histology, and patients previously treated with anti–PD-(L)1 therapy.<br /><br />3. **Sensitivity Analyses:** Even after adjusting for various potential biases, such as differences in data collection periods or prior treatment exposure, the benefit persisted, underscoring the robustness of the findings.<br /><br />4. **Study Design:** Participants were drawn from the Flatiron Health database comprising electronic health records (EHRs) focusing on advanced NSCLC. The study included 102 patients on sotorasib and 58 on docetaxel in the 2L setting, with respective cohort expansions for higher treatment lines to balance characteristics through weighting. <br /><br />This research, being the first real-world analysis of its kind, adds evidence that sotorasib might offer a survival advantage over traditional chemotherapies for this specific genetic mutation in NSCLC, potentially influencing treatment protocols in clinical settings. The study was funded by Amgen Inc. and involved experts from various institutions, including the Sarah Cannon Research Institute and Duke University.

Asset Subtitle

Melissa Johnson

Meta Tag

Speaker Melissa Johnson

Topic Metastatic NSCLC – Targeted Therapy

Keywords

Sotorasib

Docetaxel

KRAS G12C mutation

Advanced NSCLC

Real-world data

Overall Survival

Subgroup Consistency

Sensitivity Analyses

Flatiron Health database

Amgen Inc.